Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study.
Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study.
复制标题
阿立哌唑治疗抽动秽语症儿童和青少年：一项开放标签安全性和耐受性研究。
DOI：
10.1089/cap.2009.0035
复制
发表时间：
2009
影响因子：
1.9
通讯作者：
Coffey,BarbaraJ
中科院分区：
文献类型：
--
作者：
Lyon,GholsonJ;Samar,Stephanie;Jummani,Rahil;Hirsch,Scott;Spirgel,Arie;Goldman,Rachel;Coffey,BarbaraJ
目的：研究阿立哌唑治疗抽动障碍(TD)儿童青少年抽动的安全性和耐受性。方法：对11例抽动障碍(TD)患者(男10例，年龄9~19岁，平均13.36岁，标准差[SD]3.33)，对既往抽动药物治疗无效或不能耐受者进行阿立哌唑治疗，为期10周。结果：阿立哌唑的平均日剂量(±SD)为4 5 ± 3 0 mg。平均(±SD)YGTSS全球严重程度评分从基线的61.82 ± 13.49降至治疗结束时的33.73 ± 15.18，平均抽动总评分由基线的28.18 ± 7.74降至治疗结束时的16.73 ± 7.54。平均(±SD)CGI-Tic严重程度评分从基线的4.45 ± 0.52(中分)降至治疗结束时的3.18 ± 0.60(轻度)。在CGI-Tic改善量表上，10例(91%)受试者在治疗结束时达到1(非常有效)或2(非常有效)。最常见的不良反应包括5例患者食欲增加和体重增加，7例患者出现轻度锥体外系反应，7例患者出现头痛和疲倦/疲劳，1例患者出现静坐不能和肌肉痉挛。结论：阿立哌唑治疗儿童和青少年TD是一种安全、可耐受的治疗方法，似乎可以减少抽动；作为一种治疗方案，值得在对照试验中进一步研究。
Objective:The aim of this study was to conduct a prospective safety and tolerability study of aripiprazole for the treatment of tics in children and adolescents with Tourette's disorder (TD).Method:Eleven subjects (10 males) with TD (age 9–19 years, mean 13.36, standard deviation [SD] 3.33) who did not respond or were unable to tolerate previous tic medication were treated with aripiprazole in an open-label, flexible-dosing study over 10 weeks. Tic severity was rated using the Yale Global Tic Severity Scale (YGTSS) and the Clinical Global Impressions Scale for tics (CGI-Tics) at baseline and at follow-up.Results:The mean (±SD) daily dose for aripiprazole was 4.5 ± 3.0 mg. Mean (±SD) YGTSS Global Severity scores reduced from 61.82 ± 13.49 at baseline to 33.73 ± 15.18 at end point; mean YGTSS total tic scores reduced from 28.18 ± 7.74 at baseline to 16.73 ± 7.54 at end point. Mean (±SD) CGI-Tic severity scores reduced from 4.45 ± 0.52 (moderate-marked) at baseline to 3.18 ± 0.60 (mild) at end point. On the CGI-Tic improvement scale, 10 (91%) subjects achieved 1 (“very much improved”) or 2 (“much improved”) at end point. Most common adverse effects included appetite increase and weight gain in 5 subjects, mild extrapyramidal effects in 7 subjects, and headaches and tiredness/fatigue in 7 subjects; 1 subject experienced akathisia and muscle cramps.Conclusion:Aripiprazole appears to be a safe and tolerable treatment in children and adolescents with TD that appears to reduce tics; it should be further investigated as a treatment option in controlled trials.